Zota Health Care: Monitoring Agency Report for Q4FY26 Preferential Issue Funds Utilization
Zota Health Care Limited filed its Monitoring Agency Report for Q4FY26, confirming utilization of funds from its ₹179.07 crore Preferential Issue. CRISIL Ratings Limited reported that funds were utilized for the 'DAVAINDIA' project expansion, working capital, and GCP, with no material deviations. The report marks the final monitoring of the issue proceeds.
This is a standard post-fundraising compliance report. It does not introduce new material information that would significantly impact the company's operations, financials, or stock price.
The announcement is a routine regulatory filing providing an update on the utilization of funds from a previous preferential issue. It confirms adherence to the stated objects without any significant positive or negative developments.
Zota Health Care Limited has submitted its Monitoring Agency Report for the quarter ended March 31, 2026. This report, issued by CRISIL Ratings Limited, details the utilization of funds raised through a Preferential Issue. The company had raised ₹179.07 crore through this issue, which was approved by the Board and members in meetings held on June 18, 2024, and July 13, 2024.
The report confirms that the utilization of funds was in line with the disclosures made in the Offer Document. The primary objects of the issue included the expansion of the ‘DAVAINDIA’ Project, working capital requirements, and General Corporate Purposes (GCP).
For the quarter ended March 31, 2026, the total utilization of funds amounted to ₹146.28 crore, with ₹32.78 crore remaining unutilized. The expansion of the ‘DAVAINDIA’ Project utilized ₹143.25 crore, working capital requirements were fully utilized at ₹26.86 crore, and GCP utilized ₹8.95 crore (specifically ₹39.93 lakh for tax payment). The report also notes that proceeds received from the conversion of warrants into equity shares during the quarter, amounting to ₹9.45 crore, were transferred to the Company’s cash credit account and subsequently to its subsidiary for utilization towards the stated objects.
CRISIL Ratings Limited has reviewed the utilization and found no material deviations. The report also states that the balance in the Escrow account as of March 31, 2026, is Nil, marking this as the final Monitoring Agency report for this Preferential Issue. The Audit Committee and the Board of Directors of Zota Health Care Limited reviewed this report through circular resolutions passed on May 13, 2026.
What to do with a filing like this
Zota Health Care LImited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zota Health Care LImited. Read the original for the full detail.